Background {#Sec1}
==========

Inappropriate use of antibiotics leads to significant clinical and economic problems due to resistant bacteria and increasingly limited anti-infective treatment options \[[@CR1], [@CR2]\]. The majority of antibiotics are prescribed in primary care, and children receive a large portion of these prescriptions \[[@CR3], [@CR4]\]. These primary care prescriptions of antibiotics are contributing to the world-wide resistance problem \[[@CR5]\] and promotion of appropriate use is still of great importance \[[@CR6]\]. Within the European Union there are large variations in outpatient antibiotic prescriptions. In the Netherlands, the level of prescriptions has traditionally been one of the lowest in Europe. In Germany, generally the prescription level is also relatively low \[[@CR3]\]. However, when it comes to antibiotic prescriptions for children and adolescents, prescriptions in Germany seem to be higher than in other countries \[[@CR7], [@CR8]\]. Regarding antibiotic resistance Germany has also slightly higher levels than the Netherlands \[[@CR9]\].

Due to a recent EU directive, patients can more easily obtain health services in other European member states. Directive 2011/24/EU creates the possibility for EU citizens to cross borders and seek healthcare in another country. This possibility for cross-border care is especially relevant for bordering regions such as the north of the Netherlands and north-west Germany, where Dutch healthcare centers can treat German patients and vice versa. Considering the potential effects of inappropriate antibiotic prescriptions in primary care, in particular antibiotic resistance development, it is relevant to look at differences in prescriptions between countries. It is therefore interesting to approach the topic of antimicrobial therapies and their possible unwanted effects by international cross-border collaboration, especially between bordering regions \[[@CR10]\]. Notably, children and adolescents represent large group of recipients of antibiotics, in particular in outpatient care \[[@CR3], [@CR4]\]. The goal of this study was to examine the prevalence and most frequently prescribed antibiotics among children and adolescents in outpatient care in adjacent Dutch and German regions, and to compare this data. We also aimed to answer if different healthcare systems influence prescribing or if prescribing in regions gets more comparable the nearer they are to the border.

Methods {#Sec2}
=======

Study design and setting {#Sec3}
------------------------

To address the question, we chose a retrospective cross-sectional study in a predominantly rural region including analysis of outpatients' data of a health insurance company and a pharmacy research database for north western Germany (postal codes 26xxx; part of Lower Saxony) and the northern Netherlands (postal codes 9xxx, Groningen/Drenthe). Both regions have no major geographic and infection risk differences, have about 1 million inhabitants and share a common green border (Fig. [1](#Fig1){ref-type="fig"}). Data comprises the year 2010 and we focused on persons aged 0 to 18 years. Orally administered antibiotics were selected based on the Anatomical Therapeutic Chemical (ATC) code J01 in the outpatient setting.Fig. 1Study regions in north of the Netherlands (postal codes 9xxx; *n* = 36,747) and north-west Germany (postal codes 26xxx; *n* = 18,374)

Data sources {#Sec4}
------------

The German data including pharmacy dispensing data come from one of the largest health insurance companies, the BARMER GEK, representing approximately 8.4 million persons nationwide (of them about 104,000 in postal codes 26xxx). In total, there were 160 different statutory health insurance companies (including BARMER GEK) covering a total of 70 million persons (87 % of the German population) at the end of 2010, while the remaining inhabitants are privately insured. The study cohort consisted of persons who were insured at least one day in each of the four quarters of 2010. Due to this criterion, the vast majority of our study cohort has been continuously insured throughout the whole year but infants born in the first quarter could also be analyzed \[[@CR11]\].

The Dutch data were derived from pharmacy dispensing data of the pharmacy research database ([www.IADB.nl](http://www.iadb.nl)). The IADB comprises prescriptions derived from 55 community pharmacies in the northern part of the Netherlands and has in total approximately 600,000 persons in the database (of them about 263,000 in postal codes 9xxx). Since Dutch patients are in general registered at one single local pharmacy in their hometown, the chance of multiple prescriptions of one person being counted in different areas is relatively small. Registration is furthermore irrespective of healthcare insurance and age, gender and prescription rates among the database population have been representative for the whole of the Netherlands \[[@CR12]\]. Prescription records are virtually complete due to the high patient-pharmacy commitment in the Netherlands, except for medication dispensed during hospitalization \[[@CR12]\].

Statistical analysis {#Sec5}
--------------------

Our main outcome was outpatient prescription prevalence, e.g. the proportion of children and adolescents receiving at least one prescription for a systemic antibiotic in 2010. Prevalence was stratified by sex, age groups (0--2, 3--6, 7--10, 11--13 and 14--17 years) and region of residence (six areas for the Netherlands and nine for Germany) alongside with 95 % confidence intervals (95 % CI). Furthermore, the most frequently prescribed antibiotic substances (by different ATC-codes) were studied. Statistical analyses were performed with SAS, Version 9.2 (SAS Institute Inc., Cary, NC). Maps were created with ESRI ArcGIS®, Version 10.2.2.

Results {#Sec6}
=======

The study cohort consisted of 36,747 children and adolescents under the age of 18 years, living in the northern Netherlands (ranging between 649--20,739 individuals per region) and 18,374 from north-west Germany (ranging between 988--4,028 individuals per region). For the Netherlands, the distribution male vs. female was 50 % vs. 50 % and for Germany 51 % vs. 49 %.

Overall, the proportion of children and adolescents receiving at least one antibiotic course in 2010 was lower in the northern Netherlands (29.8 %; 95 % CI: 29.3--30.3) compared to north-west Germany (38.9 %; 95 % CI: 38.2--39.6). There were small area variations ranging from 27.0 to 36.4 % in the northern Netherlands and from 35.1 to 44.1 % in north-west Germany (Fig. [2](#Fig2){ref-type="fig"}). Prevalence stratified by region, sex and age groups is shown in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. The age groups with the highest proportion of prescriptions were children between 0--2 years (northern Netherlands vs. north-west Germany: 43.1 % vs. 49.9 %) and those between 3--6 years (37.4 % vs. 54.8 %). The proportion was considerably higher in Germany than in the Netherlands in all age groups, for males and for females. Males had a lower prevalence of antibiotic prescriptions than females for both Netherlands and Germany in all age groups, except for children aged 0--2 years old (Table [2](#Tab2){ref-type="table"}).Fig. 2Small area variations (by postal codes) in the proportion of children and adolescents with prescriptions of antibiotics in the northern Netherlands and north-west GermanyTable 1Small area variations (by postal codes) in the proportion of children and adolescents with prescriptions of antibiotics in the northern Netherlands and north-west Germany (with 95 % CI), by sexRegion/postal code (number of children included)MalesFemalesTotalNetherlands 95, 96 (*n* = 10,439)31.6 % (30.3--32.9)34.7 % (33.4--36.0)33.2 % (32.3--34.1) 90, 91, 99 (*n* = 649)27.7 % (23.0--32.8)26.1 % (21.3--31.4)27.0 % (23.6--30.6) 92, 98 (*n* = 1,898)36.2 % (33.2--39.4)36.6 % (33.5--39.8)36.4 % (34.2--38.6) 93 (*n* = 868)28.0 % (23.9--32.5)28.0 % (23.8--32.5)28.0 % (25.0--31.1) 94 (*n* = 2,154)28.0 % (25.3--30.8)29.2 % (26.5--31.9)28.6 % (26.7--30.6) 97 (*n* = 20,739)26.7 % (25.8--27.6)28.9 % (28.0--29.8)27.8 % (27.2--28.4)Germany 261 (*n* = 4,028)35.3 % (33.2--37.4)34.9 % (32.8--37.0)35.1 % (33.6--36.6) 262 (*n* = 988)35.0 % (30.8--39.3)42.1 % (37.6--46.6)38.5 % (35.4--41.6) 263 (*n* = 1,744)31.9 % (28.8--35.1)38.4 % (35.2--41.7)35.1 % (32.9--37.4) 264 (*n* = 1,959)36.5 % (33.5--39.6)34.9 % (31.8--37.9)35.7 % (33.6--37.8) 265 (*n* = 1,102)40.8 % (36.7--45.1)41.4 % (37.2--45.6)41.1 % (38.2--44.1) 266 (*n* = 2,476)38.5 % (35.8--41.2)40.0 % (37.2--42.8)39.2 % (37.3--41.2) 267 (*n* = 1,263)40.7 % (36.7--44.7)43.6 % (39.8--47.5)42.2 % (39.5--45.0) 268 (*n* = 3,642)42.0 % (39.8--44.3)46.2 % (43.9--48.6)44.1 % (42.5--45.7) 269 (*n* = 1,172)41.1 % (37.2--45.1)40.8 % (36.7--45.0)41.0 % (38.1--43.8)Table 2Proportion of children and adolescents with prescriptions of antibiotics in the northern Netherlands and north-west Germany (with 95 % CI), by sex and age groupMalesFemalesTotalAgeNetherlands (*n* = 18,229)Germany (*n* = 9,283)Netherlands (*n* = 18,518)Germany (*n* = 9,091)Netherlands (*n* = 36,747)Germany (*n* = 18,374)0--2 years. (*n* = 8,075 resp. *n* = 1,770)44.5 % (43.0--46.0)53.1 % (49.8--56.4)41.5 % (39.9--43.1)46.6 % (43.2--50.0)43.1 % (42.0--44.2)49.9 % (47.6--52.3)3--6 years. (*n* = 7,464 resp. *n*∓3,488)35.2 % (33.8--36.8)56.2 % (53.9--58.5)39.9 % (38.2--41.5)53.3 % (50.9--55.7)37.4 % (36.3--38.5)54.8 % (53.2--56.5)7--10 year. (*n* = 6,916 resp. *n* = 4,292)19.6 % (18.3--20.9)35.4 % (33.3--37.4)27.7 % (26.1--29.2)37.4 % (35.4--39.5)23.4 % (22.4--24.4)36.4 % (35.0--37.9)11--13 years. (*n* = 5,078 resp. *n* = 3,733)16.3 % (14.9--17.8)27.7 % (25.6--29.8)19.6 % (18.0--21.2)28.9 % (26.9--31.0)17.9 % (16.8--18.9)28.3 % (26.9--29.8)14--17 years. (*n* = 9,214 resp. *n* = 5,091)20.7 % (19.4--22.1)29.1 % (27.4--30.9)25.2 % (24.0--26.3)39.1 % (37.2--41.0)23.4 % (22.6--24.3)34.0 % (32.7--35.3)Total (*n* = 36,747 resp. *n* = 18,374)28.7 % (28.0--29.4)37.9 % (36.9--38.9)30.9 % (30.3--31.6)39.9 % (38.9--40.9)29.8 % (29.3--30.3)38.9 % (38.2--39.6)

Distributions of the antibiotic substances varied between the two bordering regions. Amoxicillin was the most frequently prescribed substance in both regions, 49.6 % of all prescriptions in the Netherlands versus 21.1 % in Germany. Another profound difference was found for second generation cephalosporins, which in the Netherlands is reserved as a second line antibiotic. These antibiotics comprised 25 % of the prescriptions in Germany and less than 0.1 % in the Netherlands.

The five most frequent prescribed antibiotics for all paediatric age groups covered 81.0 % of the total number of prescriptions in the Netherlands vs. 64.3 % in Germany (Table [3](#Tab3){ref-type="table"}). In both countries, the percentage of top 5 prescriptions decreased with age: in the Netherlands from 94.2 % in 0--2 year olds to 69.0 % in 14--17 year olds and in Germany from 76.4 % in 0--2 year olds to 53.6 % in 14--17 year olds.Table 3The top 5 most prescribed antibiotic substances in the northern Netherlands and north-west Germany, by age group and the totalAgeNetherlands%Germany%0--2 years. 1stAmoxicillin70.7 %Cefaclor29.5 % 2ndAmoxicillin-clavulanate10.5 %Amoxicillin22.0 % 3rdClarithromycin6.6 %Erythromycin14.2 % 4thSulfamethoxazole and trimethoprim3.7 %Cefuroxime5.9 % 5thPheneticillin2.7 %Phenoxymethylpenicillin4.8 %Total of the 5 most prescribed94.2 %76.4 %3--6 years. 1stAmoxicillin56.1 %Amoxicillin22.2 % 2ndAmoxicillin-clavulanate13.6 %Cefaclor21.9 % 3rdClarithromycin8.9 %Phenoxymethylpenicillin10.5 % 4thPheneticillin4.5 %Erythromycin10.0 % 5thSulfamethoxazole and trimethoprim4.2 %Sulfamethoxazole and trimethoprim7.9 %Total of the 5 most prescribed87.4 %72.6 %7--10 year. 1stAmoxicillin43.5 %Amoxicillin19.7 % 2ndAmoxicillin-clavulanate13.5 %Cefaclor18.1 % 3rdClarithromycin9.6 %Erythromycin11.2 % 4thNitrofurantoin7.8 %Phenoxymethylpenicillin11.1 % 5thFlucloxacillin6.6 %Sulfamethoxazole and trimethoprim8.1 %Total of the 5 most prescribed81.1 %68.2 %11--13 years. 1stAmoxicillin36.5 %Amoxicillin22.4 % 2ndAmoxicillin-clavulanate13.2 %Cefaclor12.6 % 3rdClarithromycin10.0 %Cefuroxime10.7 % 4thNitrofurantoin8.9 %Sulfamethoxazole and trimethoprim8.7 % 5thSulfamethoxazole and trimethoprim5.8 %Phenoxymethylpenicillin8.1 %Total of the 5 most prescribed74.4 %62.5 %14--17 years. 1stNitrofurantoin19.7 %Amoxicillin19.7 % 2ndAmoxicillin16.0 %Cefuroxime9.4 % 3rdDoxycycline14.8 %Azithromycin8.4 % 4thAmoxicillin-clavulanate10.5 %Phenoxymethylpenicillin8.1 % 5thPheneticillin8.1 %Sulfamethoxazole and trimethoprim8.0 %Total of the 5 most prescribed69.0 %53.6 %0--17 years. 1stAmoxicillin49.6 %Amoxicillin21.1 % 2ndAmoxicillin-clavulanate11.9 %Cefaclor17.3 % 3rdClarithromycin7.7 %Phenoxymethylpenicillin9.0 % 4thNitrofurantoin7.0 %Erythromycin9.0 % 5thPheneticillin4.8 %Cefuroxime7.9 %Total of the 5 most prescribed81.0 %64.3 %

Discussion {#Sec7}
==========

Study findings and implications {#Sec8}
-------------------------------

This is one of the first studies to look at outpatient antibiotic prescriptions among children in the bordering regions of two countries. Considering the importance of appropriate antibiotic use, the ability for patients to seek healthcare services abroad, and the large differences between healthcare systems and guidelines, a cross-border comparison is of great interest. Furthermore, these comparisons may be beneficial to inform healthcare providers and to discuss best clinical practice. We observed considerable differences between the two countries. This may indicate that improvements can be achieved. Mainly on the distribution of substances, differences were profound: second generation cephalosporins (i.e., mostly oral cefuroxime) were prescribed in 25 % of the cases for the German patients, while almost none of the Dutch children received this type (\<0.1 %). Given the low rate of oral bioavailability and the high selective pressure due to these substances, they are avoided wherever possible in ambulatory paediatric care in the Netherlands. It would be highly interesting and relevant to perform further research into the reasons for prescribing second generation cephalosporins in Germany and its long term effects.

These differences in prescriptions of antibiotics for outpatients between European countries have been reported earlier, although not for bordering regions. There are however comparisons showing differences between Germany and the Netherlands in general \[[@CR3]\], as well as for children \[[@CR9]\]. In the Netherlands, guideline adherence is higher compared to Germany \[[@CR13]\], which might also be a reason for different distributions of substances between both countries. In 7--17 years old children, nitrofurantoin was among the top 5 antibiotics in the Netherlands but not in Germany. In Germany, there may still be hesitance to prescribe nitrofurantoin due to a history of warnings in the past (pulmonary fibrosis, neuropathy and liver damage) \[[@CR14]\].

In addition, the occurrence of resistant bacteria such as MRSA differs also significantly between the bordering regions of the Netherlands and Germany, with up to 32-fold higher MRSA incidence in the German border region compared to the adjacent Dutch border region \[[@CR15]\]. In addition, higher resistance rates were also observed for classical community-acquired pathogens such as pneumococci where penicillin-resistance involved 1.9 % of invasive isolates in Germany vs. 0.2 % in the Netherlands in 2013 \[[@CR16]\]. The Dutch prevalence data observed in this study are comparable to earlier studies, indicating a quite stable use and also corroborating the fact that the IADB database can be considered as representative for the whole county \[[@CR9], [@CR17]\]. Comparing various German studies there is a bit more variation, but it is known that there is a quite large regional variation of outpatient antibiotic prescriptions within the country. The north-western part of Germany, which is included in this study, is one of the higher prescribing regions \[[@CR18], [@CR19]\].

For both datasets, clinical indications for the prescriptions analyzed were not known. For the Netherlands, a large survey showed that the primary diagnosis for children coming to general practitioners is lower respiratory tract infections \[[@CR20]\]. Antibiotic prescriptions by general practitioners for children in the Netherlands are mainly for acute otitis media and bronchitis, and especially broad-spectrum antibiotics are still prescribed inappropriately \[[@CR21]\]. Dutch guidelines regarding antibiotic treatment are very strict. Otitis media guidelines recommend antibiotics only when there are other risk factors for complications or with severe general symptoms \[[@CR22]\]. For respiratory tract infections, antibiotics are only recommended in the case of pneumonia \[[@CR23]\]. In Germany most diagnoses for children (0--15 years) in an outpatient setting were upper respiratory tract infections without a focus, fever without a focus and acute bronchitis \[[@CR24]\]. Antibiotic prescriptions for this group are mainly given for acute tonsillitis, bronchitis and otitis media, for all of which appropriateness of antibiotics is debatable \[[@CR8]\]. The German guideline for otitis media recommends antibiotic treatment only to be started after two days, thereby being less conservative than the Dutch counterpart \[[@CR25]\]. The general guideline for bronchitis states that when uncomplicated, antibiotics are not recommended and should be avoided \[[@CR26]\].

Influence of parents on the prescribed antibiotic treatment seems to be relatively small. A European survey, although not performed in the Netherlands or Germany, showed that patients tend to adhere to the decision of the general practitioner even when they disagree \[[@CR27]\]. When they disagree, they have a tendency to be more conservative than the physician \[[@CR28]\]. A survey in Germany confirms this and shows that the large majority of patients understand the limitations of antibiotic treatment for indications like the common cold \[[@CR29]\]. The influence of the family practitioner or paediatrician thus seems to be often underestimated, whereas they show indeed a high inter-individual variation in their prescription pattern \[[@CR30]\]. Perceptions of antibiotic resistance among general practitioners also differs between countries \[[@CR31]\], probably also leading to different prescription behaviour. A combination of these aspects is most likely leading to the differences between the Netherlands and Germany.

Strengths and limitations {#Sec9}
-------------------------

The major strength of this study is the unique dataset of two bordering regions coming from countries with different healthcare systems and antibiotic prescribing policies. Other studies compared nationwide data (either from a subset of databases or up to 100 % coverage such as most of ESAC). However, as shown here for the first time, there are also large small area variations among and between bordering regions from two different countries. Studies comparing national consumption data, aggregate these data and variations within a country are then lost, making it impossible to effectively compare bordering regions. We were able to include about 37,000 children and adolescents living in the northern Netherlands as well as 18,000 living in north-west Germany. However, especially in the Netherlands our cohort size differs relevantly per area (depending on the distribution of pharmacies included in the IADB.nl database). Therefore, in some areas several postal codes were combined. Age distribution and drug utilization of the patients included in the database is, however, representative for the total Dutch population \[[@CR12]\]. For Germany, the sample size was somewhat smaller than for the Netherlands. German data were derived from a large health insurance fund and we know that differences exist regarding socioeconomic status and morbidity between these insurance funds \[[@CR32]\]. Such differences were found in children and adolescents, too, but the utilization of medications within the specific fund we used was quite comparable to the complete German population \[[@CR33]\]. Unfortunately, we had no access to diagnoses and indications for which antibiotics were prescribed. These data would be relevant in determining the appropriateness of the (antibiotic) treatments, and also could shed light on the question if some patients might even be undertreated. It seems, that coming closer to the border increases antibiotic consumption in both countries. One explanation might be, that these parts of the country are furthest away from an academic centre. These (rural) parts of the countries are also socio-economically weaker compared to the more densely populated parts. Such a lower socio-economic status appears to influence antibiotic prescribing, although it is unclear to which extent \[[@CR34], [@CR35]\]. However, more precise information is not available within the datasets used. This study should form a starting point for (regional) antimicrobial stewardship programs focusing on general practitioners and outpatients. This group is still somewhat neglected in stewardship programs, but these data show that there is a lot to gain.

It is important to keep in mind that the structures and organization of the two healthcare systems differ substantially between the Netherlands and Germany. In the former, there are only family practitioners in private practice, whereas nearly all specialists are working in outpatient clinics in (larger) hospitals. Hence, the data analyzed in this study primarily contain prescription data for these family physicians. In Germany, the majority of medical specialists, including paediatricians, is working in private practice (or consortiums). The German data set comprised also the data from these specialists. Previous analysis for the whole of Germany showed that 49 % of the prescriptions came from paediatricians and 35 % from general practitioners \[[@CR19]\]. This may also influence individual prescribing patterns due to a variety of reasons and cause a bias due to more severe cases treated by specialists on the German side of the border, although we hypothesize that severe cases are most likely send to a hospital and are thus not included in this dataset. One may speculate that the more individualized healthcare system for primary care in Germany might lead to a more heterogeneous healthcare behaviour than the more peer group-dependent gatekeeper system in the Netherlands. Prescribing patterns are influenced by many different factors. Other differences between the Netherlands and Germany (e.g. medical education, performing microbiological diagnostics or healthcare insurance system) are most likely also of influence, however to which degree is uncertain and should be subject to further investigation.

Conclusions {#Sec10}
===========

Concluding, this study shows clear differences between primary care antibiotic prescriptions for children and adolescents in the bordering regions of the Netherlands and Germany. Especially in the age group of 3--6 year-old children, prescriptions are more frequent in Germany. Overall there also seems to be a tendency to prescribe broader substances in Germany compared to the Netherlands. An evaluation like this is especially interesting, considering that most antibiotics in a primary care setting are prescribed for children. Keeping in mind the effects that sub-optimal antibiotic treatments can have, these comparisons of bordering regions between two countries provide an opportunity to learn from each other and collaborate internationally in order to counteract the problems of rising antibiotic resistance from a first line of care perspective.
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